Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 14 de 14
Filtrar
1.
Immunology ; 162(2): 208-219, 2021 02.
Artículo en Inglés | MEDLINE | ID: mdl-33010039

RESUMEN

Immunogenicity risk assessment is a critical element in protein drug development. Currently, the risk assessment is most often performed using MHC-associated peptide proteomics (MAPPs) and/or T-cell activation assays. However, this is a highly costly procedure that encompasses limited sensitivity imposed by sample sizes, the MHC repertoire of the tested donor cohort and the experimental procedures applied. Recent work has suggested that these techniques could be complemented by accurate, high-throughput and cost-effective prediction of in silico models. However, this work covered a very limited set of therapeutic proteins and eluted ligand (EL) data. Here, we resolved these limitations by showcasing, in a broader setting, the versatility of in silico models for assessment of protein drug immunogenicity. A method for prediction of MHC class II antigen presentation was developed on the hereto largest available mass spectrometry (MS) HLA-DR EL data set. Using independent test sets, the performance of the method for prediction of HLA-DR antigen presentation hotspots was benchmarked. In particular, the method was showcased on a set of protein sequences including four therapeutic proteins and demonstrated to accurately predict the experimental MS hotspot regions at a significantly lower false-positive rate compared with other methods. This gain in performance was particularly pronounced when compared to the NetMHCIIpan-3.2 method trained on binding affinity data. These results suggest that in silico methods trained on MS HLA EL data can effectively and accurately be used to complement MAPPs assays for the risk assessment of protein drugs.


Asunto(s)
Presentación de Antígeno/inmunología , Antígenos HLA-DR/inmunología , Proteínas/inmunología , Epítopos de Linfocito T/inmunología , Antígenos de Histocompatibilidad Clase II/inmunología , Humanos , Ligandos , Activación de Linfocitos/inmunología , Unión Proteica/inmunología , Proteómica/métodos , Medición de Riesgo
2.
Eur J Immunol ; 46(4): 952-63, 2016 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-26786702

RESUMEN

Osteoclast-associated receptor (OSCAR) is an activating receptor expressed by human myeloid cells. Collagen type I (ColI) and collagen type II (ColII) serve as ligands for OSCAR. OSCAR-collagen interaction stimulates RANK-dependent osteoclastogenesis. We have recently reported that OSCAR promotes functional maturation of monocyte-derived dendritic cells. OSCAR is upregulated on monocytes from rheumatoid arthritis (RA) patients with active disease, and these monocytes show an increased proosteoclastogenic potential. In the current study, we have addressed a functional role for an OSCAR-collagen interaction on monocytes. We show that OSCAR-ColII signaling promoted the survival of monocytes. Moreover, ColII stimulated the release of proinflammatory cytokines by monocytes from healthy donors, which could be completely blocked by an anti-OSCAR monoclonal antibody. Mononuclear cells from the synovial fluid of RA patients plated on ColII secreted TNF-α and IL-8 in an OSCAR-dependent manner. Global RNA profiling showed that components of multiple signaling pathways relevant to RA pathogenesis are regulated at the transcriptional level by OSCAR in monocytes. Thus, OSCAR can play a proinflammatory role in monocyte-derived cells and may contribute crucially on multiple levels to RA pathogenesis.


Asunto(s)
Artritis Reumatoide/patología , Colágeno Tipo II/metabolismo , Inflamación/inmunología , Monocitos/inmunología , Receptores de Superficie Celular/metabolismo , Anticuerpos Monoclonales/inmunología , Artritis Reumatoide/inmunología , Diferenciación Celular/inmunología , Células Cultivadas , Colágeno Tipo I/metabolismo , Células Dendríticas/inmunología , Humanos , Mediadores de Inflamación/metabolismo , Interleucina-8/metabolismo , Osteoclastos/citología , Transducción de Señal/inmunología , Líquido Sinovial/citología , Factor de Necrosis Tumoral alfa/metabolismo
3.
J Immunol ; 194(7): 3169-79, 2015 Apr 01.
Artículo en Inglés | MEDLINE | ID: mdl-25725106

RESUMEN

Osteoclast-associated receptor (OSCAR) is widely expressed on human myeloid cells. Collagen types (Col)I, II, and III have been described as OSCAR ligands, and ColII peptides can induce costimulatory signaling in receptor activator for NF-κB-dependent osteoclastogenesis. In this study, we isolated collagen as an OSCAR-interacting protein from the membranes of murine osteoblasts. We have investigated a functional outcome of the OSCAR-collagen interaction in human monocyte-derived dendritic cells (DCs). OSCAR engagement by ColI/II-induced activation/maturation of DCs is characterized by upregulation of cell surface markers and secretion of cytokines. These collagen-matured DCs (Col-DCs) were efficient drivers of allogeneic and autologous naive T cell proliferation. The T cells expanded by Col-DCs secreted cytokines with no clear T cell polarization pattern. Global RNA profiling revealed that multiple proinflammatory mediators, including cytokines and cytokine receptors, components of the stable immune synapse (namely CD40, CD86, CD80, and ICAM-1), as well as components of TNF and TLR signaling, are transcriptional targets of OSCAR in DCs. Our findings indicate the existence of a novel pathway by which extracellular matrix proteins locally drive maturation of DCs during inflammatory conditions, for example, within synovial tissue of rheumatoid arthritis patients, where collagens become exposed during tissue remodeling and are thus accessible for interaction with infiltrating precursors of DCs.


Asunto(s)
Diferenciación Celular , Colágeno/metabolismo , Células Dendríticas/citología , Células Dendríticas/metabolismo , Monocitos/citología , Monocitos/metabolismo , Receptores de Superficie Celular/metabolismo , Transducción de Señal , Antígenos de Superficie/metabolismo , Diferenciación Celular/efectos de los fármacos , Diferenciación Celular/inmunología , Supervivencia Celular/efectos de los fármacos , Quimiocinas/biosíntesis , Técnicas de Cocultivo , Colágeno/farmacología , Citocinas/biosíntesis , Células Dendríticas/efectos de los fármacos , Regulación de la Expresión Génica , Humanos , Inmunofenotipificación , Ligandos , Activación de Linfocitos/efectos de los fármacos , Activación de Linfocitos/inmunología , Monocitos/efectos de los fármacos , FN-kappa B/metabolismo , Linfocitos T/inmunología , Linfocitos T/metabolismo
4.
J Immunol ; 192(8): 3540-7, 2014 Apr 15.
Artículo en Inglés | MEDLINE | ID: mdl-24616477

RESUMEN

Urokinase plasminogen activator (uPA) and its receptor (uPAR) coordinate a plasmin-mediated proteolytic cascade that has been implicated in cell adhesion, cell motility, and matrix breakdown, for example, during inflammation. As part of their function during inflammatory responses, macrophages move through tissues and encounter both two-dimensional (2D) surfaces and more complex three-dimensional (3D) interstitial matrices. Based on approaches employing uPA gene-deficient macrophages, plasminogen supplementation, and neutralization with specific protease inhibitors, it is reported in this study that uPA activity is a central component of the invasion of macrophages through a 3D Matrigel barrier; it also has a nonredundant role in macrophage-mediated matrix degradation. For murine macrophages, matrix metalloproteinase-9 activity was found to be required for these uPA-mediated effects. Evidence for a unique role for uPA in the inverse relationship between macrophage adhesion and 2D migration was also noted: macrophage adhesion to vitronectin was enhanced by uPA and blocked by plasminogen activator inhibitor-1, the latter approach also able to enhance in turn the 2D migration on this matrix protein. It is therefore proposed that uPA can have a key role in the inflammatory response at several levels as a central regulator of macrophage 3D invasion, matrix remodeling, and adhesion.


Asunto(s)
Movimiento Celular , Matriz Extracelular/metabolismo , Macrófagos/fisiología , Activador de Plasminógeno de Tipo Uroquinasa/metabolismo , Animales , Adhesión Celular/genética , Movimiento Celular/genética , Activación Enzimática , Femenino , Humanos , Metaloproteinasa 9 de la Matriz/metabolismo , Ratones , Ratones Noqueados , Modelos Biológicos , Proteolisis , Activador de Plasminógeno de Tipo Uroquinasa/genética
5.
Int J Pharm ; 631: 122490, 2023 Jan 25.
Artículo en Inglés | MEDLINE | ID: mdl-36521637

RESUMEN

The immunogenicity risk of therapeutic protein aggregates has been extensively investigated over the past decades. While it is established that not all aggregates are equally immunogenic, the specific aggregate characteristics, which are most likely to induce an immune response, remain ambiguous. The aim of this study was to perform comprehensive in vitro and in vivo immunogenicity assessment of human insulin aggregates varying in size, structure and chemical modifications, while keeping other morphological characteristics constant. We found that flexible aggregates with highly altered secondary structure were most immunogenic in all setups, while compact aggregates with native-like structure were found to be immunogenic primarily in vivo. Moreover, sub-visible (1-100 µm) aggregates were found to be more immunogenic than sub-micron (0.1-1 µm) aggregates, while chemical modifications (deamidation, ethylation and covalent dimers) were not found to have any measurable impact on immunogenicity. The findings highlight the importance of utilizing aggregates varying in few characteristics for assessment of immunogenicity risk of specific morphological features and may provide a workflow for reliable particle analysis in biotherapeutics.


Asunto(s)
Agregado de Proteínas , Humanos
6.
Clin Immunol ; 145(1): 1-10, 2012 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-22885146

RESUMEN

Human B cells are able to secrete IL-10 after stimulation with mitogens, but their ability to produce IL-10 and regulate T-cell responses after stimulation with self-antigens is unclear. We co-cultured thyroglobulin-pulsed B cells from healthy donors with autologous T cells and observed production of IL-10 and TGF-ß, in addition to TNF-α and IL-6. Pulsing with foreign antigen, tetanus toxoid (TT), induced a Th1-response with minimal IL-10 production. After thyroglobulin-pulsing, 1.10±0.50% of B cells and 1.00±0.20% of CD4(+) T cells produced IL-10, compared to 0.29±0.19% of B cells (P=0.01) and 0.13±0.15% of CD4(+) T cells (P=0.006) following TT-pulsing. Thyroglobulin-stimulated, IL-10-secreting B cells were enriched within CD5(+) and CD24(high) cells. While thyroglobulin-pulsed B cells induced only modest proliferation of CD4(+) T cells, B cells pulsed with TT induced vigorous proliferation. Thus, B cells mediate self-antigen-specific IL-10, TNF-α and IL-6 production in co-cultures with T cells and contribute actively to these cytokine secretions.


Asunto(s)
Autoantígenos/inmunología , Linfocitos B/inmunología , Interleucina-10/inmunología , Subgrupos de Linfocitos T/inmunología , Tiroglobulina/inmunología , Autoantígenos/farmacología , Linfocitos B/citología , Técnicas de Cocultivo , Humanos , Interleucina-10/biosíntesis , Interleucina-6/biosíntesis , Interleucina-6/inmunología , Activación de Linfocitos/efectos de los fármacos , Linfocitos T/citología , Linfocitos T/inmunología , Toxoide Tetánico/inmunología , Toxoide Tetánico/farmacología , Tiroglobulina/farmacología , Factor de Necrosis Tumoral alfa/biosíntesis , Factor de Necrosis Tumoral alfa/inmunología
7.
Mol Metab ; 24: 30-43, 2019 06.
Artículo en Inglés | MEDLINE | ID: mdl-31079959

RESUMEN

OBJECTIVE: Increasing the amounts of functionally competent brown adipose tissue (BAT) in adult humans has the potential to restore dysfunctional metabolism and counteract obesity. In this study, we aimed to characterize the human perirenal fat depot, and we hypothesized that there would be regional, within-depot differences in the adipose signature depending on local sympathetic activity. METHODS: We characterized fat specimens from four different perirenal regions of adult kidney donors, through a combination of qPCR mapping, immunohistochemical staining, RNA-sequencing, and pre-adipocyte isolation. Candidate gene signatures, separated by adipocyte morphology, were recapitulated in a murine model of unilocular brown fat induced by thermoneutrality and high fat diet. RESULTS: We identified widespread amounts of dormant brown adipose tissue throughout the perirenal depot, which was contrasted by multilocular BAT, primarily found near the adrenal gland. Dormant BAT was characterized by a unilocular morphology and a distinct gene expression profile, which partly overlapped with that of subcutaneous white adipose tissue (WAT). Brown fat precursor cells, which differentiated into functional brown adipocytes were present in the entire perirenal fat depot, regardless of state. We identified SPARC as a candidate adipokine contributing to a dormant BAT state, and CLSTN3 as a novel marker for multilocular BAT. CONCLUSIONS: We propose that perirenal adipose tissue in adult humans consists mainly of dormant BAT and provide a data set for future research on factors which can reactivate dormant BAT into active BAT, a potential strategy for combatting obesity and metabolic disease.


Asunto(s)
Adipocitos Marrones/citología , Tejido Adiposo Pardo/citología , Riñón/citología , Células Madre Mesenquimatosas/citología , Adipocitos Marrones/metabolismo , Adulto , Anciano , Animales , Proteínas de Unión al Calcio/genética , Proteínas de Unión al Calcio/metabolismo , Células Cultivadas , Femenino , Humanos , Masculino , Proteínas de la Membrana/genética , Proteínas de la Membrana/metabolismo , Células Madre Mesenquimatosas/metabolismo , Ratones , Persona de Mediana Edad , Osteonectina/genética , Osteonectina/metabolismo
8.
PLoS One ; 13(5): e0197407, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-29758051

RESUMEN

Immunogenicity is a major concern in drug development as anti-drug antibodies in many cases affect both patient safety and drug efficacy. Another concern is often the limited half-life of drugs, which can be altered by different chemical modifications, like acylation with fatty acids. However, acylation with fatty acids has been shown in some cases to modulate T cell activation. Therefore, to understand the role of acylation with fatty acids on immunogenicity we tested three immunogenic non-acylated peptides and 14 of their acylated analogues for binding to 26 common HLA class II alleles, and their ability to activate T cells in an ex vivo T cell assay. Changes in binding affinity associated with acylation with fatty acids were typically modest, though a significant decrease was observed for influenza HA acylated with a stearic acid, and affinities for DQ alleles were consistently increased. Importantly, we showed that for all three immunogenic peptides acylation with fatty acids decreased their capacity to activate T cells, a trend particularly evident with longer fatty acids typically positioned within the peptide HLA class II binding core region, or when closer to the C-terminus. With these results we have demonstrated that acylation with fatty acids of immunogenic peptides can lower their stimulatory capacity, which could be important knowledge for drug design and immunogenicity mitigation.


Asunto(s)
Acilación , Ácidos Grasos/química , Antígenos de Histocompatibilidad Clase II/química , Péptidos/química , Linfocitos T/inmunología , Alelos , Citocinas/metabolismo , Epítopos/química , Exenatida/inmunología , Factor VIIa/inmunología , Variación Genética , Glicoproteínas Hemaglutininas del Virus de la Influenza/inmunología , Humanos , Activación de Linfocitos , Unión Proteica , Dominios Proteicos , Proteínas Recombinantes/inmunología , Transducción de Señal , Linfocitos T/metabolismo
9.
PLoS One ; 12(5): e0178544, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28562666

RESUMEN

Many biopharmaceuticals (BPs) are known to be immunogenic in the clinic, which can result in modified pharmacokinetics, reduced efficacy, allergic reactions and anaphylaxis. During recent years, several technologies to predict immunogenicity have been introduced, but the predictive value is still considered low. Thus, there is an unmet medical need for optimization of such technologies. The generation of T cell dependent high affinity anti-drug antibodies plays a key role in clinical immunogenicity. This study aimed at developing and evaluating a novel in vitro T cell:PBMC assay for prediction of the immunogenicity potential of BPs. To this end, we assessed the ability of infliximab (anti-TNF-α), rituximab (anti-CD20), adalimumab (anti-TNF-α) and natalizumab (anti-α4-integrin), all showing immunogenicity in the clinic, to induce a CD4+ T cells response. Keyhole limpet hemocyanin (KLH) and cytomegalovirus pp65 protein (CMV) were included as neo-antigen and recall antigen positive controls, respectively. By analyzing 26 healthy donors having HLA-DRB1 alleles matching the European population, we calculated the frequency of responding donors, the magnitude of the response, and the frequency of BP-specific T cells, as measured by 3[H]-thymidine incorporation and ELISpot IL-2 secretion. KLH and CMV demonstrated a strong T cell response in all the donors analyzed. The frequency of responding donors to the BPs was 4% for infliximab, 8% for adalimumab, 19% for rituximab and 27% for natalizumab, which is compared to and discussed with their respective observed clinical immunogenicity. This study further complements predictive immunogenicity testing by quantifying the in vitro CD4+ T cell responses to different BPs. Even though the data generated using this modified method does not directly translate to the clinical situation, a high sensitivity and immunogenic potential of most BPs is demonstrated.


Asunto(s)
Anticuerpos/inmunología , Linfocitos T CD4-Positivos/inmunología , Donantes de Tejidos , Ensayo de Inmunoadsorción Enzimática , Antígenos HLA/inmunología , Haplotipos , Humanos
10.
Mol Metab ; 6(7): 770-779, 2017 07.
Artículo en Inglés | MEDLINE | ID: mdl-28702332

RESUMEN

OBJECTIVE: MicroRNAs (miRNAs) are increasingly recognized as fine-tuning regulators of metabolism, and are dysregulated in several disease conditions. With their capacity to rapidly change gene expression, miRNAs are also important regulators of development and cell differentiation. In the current study, we describe an impaired myogenic capacity of muscle stem cells isolated from humans with type 2 diabetes (T2DM) and assess whether this phenotype is regulated by miRNAs. METHODS: We measured global miRNA expression during in vitro differentiation of muscle stem cells derived from T2DM patients and healthy controls. RESULTS: The mir-23b/27b cluster was downregulated in the cells of the patients, and a pro-myogenic effect of these miRNAs was mediated through the p53 pathway, which was concordantly dysregulated in the muscle cells derived from humans with T2DM. CONCLUSIONS: Our results indicate that we have identified a novel pathway for coordination of myogenesis, the miR-23b/27b-p53 axis that, when dysregulated, potentially contributes to a sustained muscular dysfunction in T2DM.


Asunto(s)
Diferenciación Celular , Diabetes Mellitus Tipo 2/metabolismo , MicroARNs/genética , Mioblastos Esqueléticos/citología , Proteína p53 Supresora de Tumor/genética , Anciano , Células Cultivadas , Diabetes Mellitus Tipo 2/genética , Diabetes Mellitus Tipo 2/patología , Regulación hacia Abajo , Femenino , Humanos , Masculino , MicroARNs/metabolismo , Persona de Mediana Edad , Desarrollo de Músculos , Mioblastos Esqueléticos/metabolismo , Proteína p53 Supresora de Tumor/metabolismo
11.
J Clin Endocrinol Metab ; 102(4): 1141-1150, 2017 04 01.
Artículo en Inglés | MEDLINE | ID: mdl-28204515

RESUMEN

Context: Offspring of women with gestational diabetes (O-GDM) or type 1 diabetes mellitus (O-T1DM) have been exposed to hyperglycemia in utero and have an increased risk of developing metabolic disease in adulthood. Design: In total, we recruited 206 adult offspring comprising the two fetal hyperglycemic groups, O-GDM and O-T1DM, and, as a control group, offspring from the background population (O-BP). Subcutaneous fat biopsies were obtained and preadipocyte cell cultures were established from adult male O-GDM (n = 18, age 30.1 ± 2.5 years), O-T1DM (n = 18, age 31.6 ± 2.2 years), and O-BP (n = 16; age, 31.5 ± 2.7 years) and cultured in vitro. Main Outcome Measures: First, we studied in vivo adipocyte histology. Second, we studied in vitro preadipocyte leptin secretion, gene expression, and LEP DNA methylation. This was studied in combination with in vitro preadipocyte lipogenesis, lipolysis, and mitochondrial respiration. Results: We show that subcutaneous adipocytes from O-GDM are enlarged compared with O-BP adipocytes. Preadipocytes isolated from male O-GDM and O-T1DM and cultured in vitro displayed decreased LEP promoter methylation, increased leptin gene expression, and elevated leptin secretion throughout differentiation, compared with adipocytes established from male O-BP. In addition, the preadipocytes demonstrated functional defects including decreased maximal mitochondrial capacity with increased lipolysis and decreased ability to store fatty acids when challenged with 3 days of extra fatty acid supply. Conclusions: Taken together, these findings show that intrinsic epigenetic and functional changes exist in preadipocyte cultures from individuals exposed to fetal hyperglycemia who are at increased risk of developing metabolic disease.


Asunto(s)
Adipocitos/fisiología , Hijos Adultos , Diabetes Mellitus Tipo 1 , Diabetes Gestacional , Hiperglucemia/congénito , Embarazo en Diabéticas , Efectos Tardíos de la Exposición Prenatal/fisiopatología , Adulto , Estudios de Casos y Controles , Células Cultivadas , Diabetes Mellitus Tipo 2/etiología , Susceptibilidad a Enfermedades , Femenino , Enfermedades Fetales/metabolismo , Enfermedades Fetales/fisiopatología , Humanos , Hiperglucemia/metabolismo , Hiperglucemia/fisiopatología , Lipólisis/fisiología , Masculino , Embarazo , Efectos Tardíos de la Exposición Prenatal/metabolismo , Factores de Riesgo
12.
J Clin Endocrinol Metab ; 101(5): 2254-64, 2016 05.
Artículo en Inglés | MEDLINE | ID: mdl-27003303

RESUMEN

CONTEXT/OBJECTIVE: Developmental programming of human muscle stem cells could in part explain why individuals born with low birth weight (LBW) have an increased risk of developing type 2 diabetes (T2D) later in life. We hypothesized that immature muscle stem cell functions including abnormal differentiation potential and metabolic function could link LBW with the risk of developing T2D. Design/Settings/Participants: We recruited 23 young men with LBW and 16 age-matched control subjects with normal birth weight. Biopsies were obtained from vastus lateralis, and muscle stem cells were isolated and cultured into fully differentiated myotubes. MAIN OUTCOME MEASURES: We studied glucose uptake, glucose transporters, insulin signaling, key transcriptional markers of myotube maturity, selected site-specific DNA methylation, and mitochondrial gene expression. RESULTS: We found reduced glucose uptake as well as decreased levels of glucose transporter-1 and -4 mRNA and of the Akt substrate of 160-kDa mRNA and protein in myotubes from LBW individuals compared with normal birth weight individuals. The myogenic differentiation markers, myogenin and myosin heavy chain 1 and 2, were decreased during late differentiation in LBW myotubes. Additionally, mRNA levels of the peroxisome proliferator-activated receptor-γ coactivator-1α and cytochrome c oxidase polypeptide 7A were reduced in LBW myotubes. Decreased gene expression was not explained by changes in DNA methylation levels. CONCLUSION: We demonstrate transcriptional and metabolic alterations in cultured primary satellite cells isolated from LBW individuals after several cell divisions, pointing toward a retained intrinsic defect conserved in these myotubes.


Asunto(s)
Fibras Musculares Esqueléticas/metabolismo , Miogenina/metabolismo , Cadenas Pesadas de Miosina/metabolismo , Músculo Cuádriceps/metabolismo , Adulto , Células Cultivadas , Transportador de Glucosa de Tipo 1/genética , Transportador de Glucosa de Tipo 1/metabolismo , Humanos , Recién Nacido de Bajo Peso , Masculino , Fibras Musculares Esqueléticas/citología , Miogenina/genética , Cadenas Pesadas de Miosina/genética , Coactivador 1-alfa del Receptor Activado por Proliferadores de Peroxisomas gamma/genética , Coactivador 1-alfa del Receptor Activado por Proliferadores de Peroxisomas gamma/metabolismo , Proteínas Proto-Oncogénicas c-akt/genética , Proteínas Proto-Oncogénicas c-akt/metabolismo , Músculo Cuádriceps/citología , Células Madre , Adulto Joven
13.
Health Aff (Millwood) ; 33(2): 336-41, 2014 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-24493777

RESUMEN

Rural residents in need of health care face many challenges. In 2009 the Leona M. and Harry B. Helmsley Charitable Trust created the Rural Healthcare Program to improve access to and quality of care in areas of the upper Midwest challenged by health care workforce shortages and low population density. The program has focused its efforts on telehealth in seven upper Midwestern states. Since 2009 the Rural Healthcare Program has approved $22 million in grants to eighty-five rural hospitals to implement eEmergency services. The service's videoconferencing technology connects rural emergency department staff with emergency physicians and nurses located at the service's "hub." Initial analyses indicate that eEmergency has helped participating rural hospitals increase patients' access to specialists, increase the use of evidence-based treatment, decrease time to transfer a patient to a facility able to provide a higher level of care, and reduce unnecessary patient transfers. This article describes the health care challenges rural communities face and the telehealth projects supported by the Helmsley Trust's Rural Healthcare Program.


Asunto(s)
Apoyo Financiero , Accesibilidad a los Servicios de Salud/economía , Servicios de Salud Rural/economía , Telemedicina/economía , Femenino , Costos de la Atención en Salud , Humanos , Masculino , Área sin Atención Médica , Evaluación de Resultado en la Atención de Salud , Estados Unidos
14.
Diabetes ; 63(1): 111-21, 2014 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-24062248

RESUMEN

Low birth weight (LBW) is associated with increased risk of the development of type 2 diabetes (T2D). The appetite-regulating hormone leptin is released from mature adipocytes, and its production may be decreased in immature preadipocytes from LBW individuals. We recruited 14 men born with LBW and 13 controls born with normal birth weight (NBW). Biopsy samples were obtained from subcutaneous abdominal fat depots, and preadipocytes were isolated and cultured. Gene expression of leptin and selected differentiation markers were analyzed during preadipocyte differentiation, and cell culture media were collected to analyze leptin secretion. DNA methylation of CpG sites in the leptin promoter was measured using pyrosequencing. We found that differentiating preadipocytes from LBW individuals showed reduced leptin gene expression and a corresponding reduced leptin release compared with NBW individuals. Mean DNA methylation of the proximal LEP promoter was increased in LBW compared with NBW individuals. The notion of impaired adipocyte maturation in LBW individuals was supported by a lower mRNA expression of the differentiation markers; fatty acid binding protein 4, peroxisome proliferator-activated receptor γ, and GLUT4. Our findings are consistent with impaired preadipocyte maturation, contributing to an increased risk of the development of T2D in LBW subjects.


Asunto(s)
Adipocitos/metabolismo , Adipogénesis/genética , Recién Nacido de Bajo Peso/metabolismo , Leptina/genética , Adipocitos/citología , Adulto , Células Cultivadas , Islas de CpG/genética , Metilación de ADN , Proteínas de Unión a Ácidos Grasos/genética , Proteínas de Unión a Ácidos Grasos/metabolismo , Transportador de Glucosa de Tipo 4/genética , Transportador de Glucosa de Tipo 4/metabolismo , Humanos , Recién Nacido , Leptina/metabolismo , Masculino , PPAR gamma/genética , PPAR gamma/metabolismo , Regiones Promotoras Genéticas , Sistema de Registros
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA